Article2006

An open-label study of escitalopram in body dysmorphic disorder

103 citations0/0 files storedInternational Clinical Psychopharmacology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Body Image and Dysmorphia Studies Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes Psychosomatic Disorders and Their Treatments

Abstract

Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with reliable and valid measures. BDD symptoms significantly improved (P<0.001), and 73.3% (n=11) of subjects were responders. Of the subjects, 46.7% were very much improved, and 33.3% were much improved. Depressive symptoms, delusionality, functioning and quality of life also significantly improved. Escitalopram was well tolerated. These preliminary data suggest that escitalopram is safe and efficacious for BDD.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 103 citations exist upstream.

References

2003SF-36 health survey: Manual and interpretation guide 1993Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.1987The Longitudinal Interval Follow-up Evaluation 1997A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale.1985The modified Hamilton rating scale for depression: Reliability and validity 2002A Randomized Placebo-Controlled Trial of Fluoxetine in Body Dysmorphic Disorder 1999Clomipramine vs Desipramine Crossover Trial in Body Dysmorphic Disorder 1998Efficacy and Safety of Fluvoxamine in Body Dysmorphic Disorder

Cited by

2023Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder 2013A Review of Body Dysmorphic Disorder and Its Presentation in Different Clinical Settings

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.